NKTX
Nkarta, Inc.
$2.40
-4.38%
$171.7M
No data for this timeframe.
Vol
Market Cap$171.7M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (90%)
Inst. Holders8 funds
Inst. Value$11.1M
Inst. Activity3 buys / 2 sells
SEC Reports5
Press Releases2
Recent Activity
May 12, 2026
SEC
Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The company highlighted FD
PRESS-RELEASE — Impact 4/10
Apr 6, 2026
SEC
Nkarta, Inc. (NKTX) has an S-3 shelf registration that became effective on April 3, 2026, allowing the company to raise
EFFECT — Impact 7/10
Mar 26, 2026
SEC
Nkarta, Inc. announced an at-the-market (ATM) offering program allowing it to sell up to $100 million in common stock th
8-K — Impact 6/10
Inst.
RENAISSANCE TECHNOLOGIES LLC — ADD
1,702,022 shares ($3.1M)
Inst.
TWO SIGMA INVESTMENTS, LP — ADD
971,982 shares ($1.8M)
May 12, 2026
earnings
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
<p>SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a cl
Apr 15, 2026
Press
Nkarta announced FDA agreement on protocol amendments for its Ntrust-1 and Ntrust-2 trials, enabling outpatient dosing,
Impact 7/10
Mar 25, 2026
Press
Nkarta reported financial results for Q4 and full year 2025, highlighting a cash balance of $295.1 million, which is exp
Impact 5/10
Price Targets
$11.20
+357.1% upside
Strong Buy
Current $2.45
Low $9.00
Median $11.00
High $16.00
5 analysts
$9.00
$16.00
Analyst Ratings
4Strong Buy
5Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 13, 2026 | Needham | REITERATE | Buy → Buy |
| Mar 31, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| Mar 26, 2026 | Needham | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.38 | $-0.39 — $-0.36 | -21% YoY | 2 |
| Next Q | $-0.39 ▲ +2.5% | $-0.41 — $-0.36 | -33% YoY | 2 |
| Current FY | $-1.52 ▲ +1.0% | $-1.60 — $-1.44 | -8% YoY | 2 |
| Next FY | $-1.73 ▲ +3.6% | $-1.95 — $-1.50 | -13% YoY | 2 |
Latest Reports
NEUTRAL
PRESS-RELEASE
4/10
Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The company highlighted FD
May 12, 2026
BULLISH
Press
7/10
Nkarta announced FDA agreement on protocol amendments for its Ntrust-1 and Ntrust-2 trials, enabling outpatient dosing,
Apr 15, 2026
BEARISH
EFFECT
7/10
Nkarta, Inc. (NKTX) has an S-3 shelf registration that became effective on April 3, 2026, allowing the company to raise
Apr 6, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| VANGUARD GROUP INC | $4.8M | — |
| RENAISSANCE TECHNOLOGIES LLC | $3.1M | ADD |
| TWO SIGMA INVESTMENTS, LP | $1.8M | ADD |
| MORGAN STANLEY | $575.6K | TRIM |
| CHARLES SCHWAB INVESTMENT MANAGEMENT | $239.0K | NEW |
8 institutional holders with $11.1M total value (5,989,299 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net buying activity: 3 institutions added/increased vs 2 reduced.
Top Institutional Holders — 2025-Q4
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | VANGUARD GROUP INC | 2,597,370 | $4.8M | 43.4% | — |
| 2 | RENAISSANCE TECHNOLOGIES LLC | 1,702,022 | $3.1M | 28.4% | ADD +48.6% |
| 3 | TWO SIGMA INVESTMENTS, LP | 971,982 | $1.8M | 16.2% | ADD +86.9% |
| 4 | MORGAN STANLEY | 311,116 | $575.6K | 5.2% | TRIM -34.3% |
| 5 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 129,175 | $239.0K | 2.2% | NEW |
| 6 | FMR LLC | 119,618 | $221.3K | 2.0% | DOUBLED +111.3% |
| 7 | BANK OF AMERICA CORP /DE/ | 110,019 | $203.5K | 1.8% | NEAR_EXIT -75.1% |
| 8 | WELLS FARGO & COMPANY/MN | 47,997 | $88.8K | 0.8% | ADD +45.8% |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| RENAISSANCE TECHNOLOGIES LLC | ADD | 1,145,077 | 1,702,022 | +48.6% | $3.1M | 2025-Q4 |
| TWO SIGMA INVESTMENTS, LP | ADD | 520,172 | 971,982 | +86.9% | $1.8M | 2025-Q4 |
| MORGAN STANLEY | TRIM | 473,217 | 311,116 | -34.3% | $575.6K | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | NEAR_EXIT | 442,493 | 110,019 | -75.1% | $203.5K | 2025-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 32,918 | 47,997 | +45.8% | $88.8K | 2025-Q4 |
| RENAISSANCE TECHNOLOGIES LLC | ADD | 696,372 | 1,145,077 | +64.4% | $2.4M | 2025-Q3 |
| TWO SIGMA INVESTMENTS, LP | ADD | 271,962 | 520,172 | +91.3% | $1.1M | 2025-Q3 |
| MORGAN STANLEY | ADD | 323,625 | 473,217 | +46.2% | $979.6K | 2025-Q3 |
| BANK OF AMERICA CORP /DE/ | TRIM | 742,718 | 442,493 | -40.4% | $916.0K | 2025-Q3 |
| UBS Group AG | NEAR_EXIT | 215,505 | 20,675 | -90.4% | $42.8K | 2025-Q3 |
| MORGAN STANLEY | TRIM | 467,481 | 323,625 | -30.8% | $537.2K | 2025-Q2 |
| TWO SIGMA INVESTMENTS, LP | ADD | 216,438 | 271,962 | +25.7% | $451.5K | 2025-Q2 |
| FMR LLC | DOUBLED | 54,976 | 116,138 | +111.3% | $192.8K | 2025-Q2 |
| MORGAN STANLEY | TRIM | 1,754,344 | 467,481 | -73.4% | $860.2K | 2025-Q1 |
| FMR LLC | TRIM | 145,311 | 54,976 | -62.2% | $101.2K | 2025-Q1 |
| MORGAN STANLEY | DOUBLED | 374,396 | 1,754,344 | +368.6% | $4.4M | 2024-Q4 |
| UBS Group AG | DOUBLED | 93,366 | 281,668 | +201.7% | $701.4K | 2024-Q4 |
| WELLS FARGO & COMPANY/MN | ADD | 24,293 | 31,056 | +27.8% | $77.3K | 2024-Q4 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | NEW | — | 145,332 | — | $656.9K | 2024-Q3 |
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
5 SEC filing reports analyzed. Sentiment: 1 bullish, 3 bearish, 0 mixed, 1 neutral. Avg impact: 6.0/10.
NEUTRAL
PRESS-RELEASE
4/10
Nkarta reported Q1 2026 EPS of -$0.37, a slight miss vs consensus of -$0.36, with no revenue. The co
May 12, 2026
BEARISH
EFFECT
7/10
Nkarta, Inc. (NKTX) has an S-3 shelf registration that became effective on April 3, 2026, allowing t
Apr 6, 2026
BEARISH
8-K
6/10
Nkarta, Inc. announced an at-the-market (ATM) offering program allowing it to sell up to $100 millio
Mar 26, 2026
BEARISH
S-3
7/10
Nkarta, Inc. (NKTX) has filed a shelf registration (S-3) to raise up to $350 million, including $100
Mar 25, 2026
BULLISH
INST-CLUSTER
6/10
Three major passive institutions — Morgan Stanley, Wells Fargo, and UBS — significantly increased th
Feb 28, 2026
Current analyst consensus: Strong Buy (90% buy). Based on 10 analysts: 4 strong buy, 5 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$11.20 mean target
+357.1% upside
Strong Buy (3.00)
$9.00 Low
$16.00 High
| Metric | Value |
|---|---|
| Current Price | $2.45 |
| Target Low | $9.00 |
| Target Mean | $11.20 |
| Target Median | $11.00 |
| Target High | $16.00 |
| # Analysts | 5 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.38 | $-0.39 | $-0.36 | -21.0% | +0.0% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next Q 2026-09-30 |
$-0.39 | $-0.41 | $-0.36 | -32.8% | +2.5% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Current FY 2026-12-31 |
$-1.52 | $-1.60 | $-1.44 | -7.8% | +1.0% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
| Next FY 2027-12-31 |
$-1.73 | $-1.95 | $-1.50 | -13.5% | +3.6% | 1↑ 0↓ | $0.0B | 0.0% | 2 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.375 | |
| 7d ago | $-0.375 | |
| 30d ago | $-0.375 | |
| 60d ago | $-0.320 | -0.055 |
| 90d ago | $-0.320 | -0.055 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 0 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 13, 2026 | Needham | REITERATE | Buy | Buy |
| Mar 31, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| Mar 26, 2026 | Needham | MAINTAIN | Buy | Buy |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 5 | 1 | 0 | 0 | 90% | |
| May 1, 2026 | 4 | 6 | 1 | 0 | 0 | 91% | |
| Apr 1, 2026 | 4 | 7 | 1 | 0 | 0 | 92% | |
| Mar 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Feb 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% | |
| Jan 1, 2026 | 4 | 7 | 2 | 0 | 0 | 85% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
May 12, 2026
earnings
Nkarta Reports First Quarter 2026 Financial Results and Corporate Highlights
<p>SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engi
May 12, 2026
earnings_calendar
NKTX Q1 2026 Earnings Scheduled — 2026-05-12
May 7, 2026
earnings_calendar
NKTX Q1 2026 Earnings Scheduled — 2026-05-07
Apr 15, 2026
fda
Nkarta Announces FDA Agreement on Outpatient Dosing of NKX019 in Autoimmune Disease, Expanding Access to Community Rheumatology Centers
<p>SOUTH SAN FRANCISCO, Calif., April 15, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing en
Mar 25, 2026
earnings
Nkarta Reports Fourth Quarter and Full Year 2025 Financial Results and Corporate Highlights
<p>SOUTH SAN FRANCISCO, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing e
Mar 19, 2026
earnings_calendar
NKTX Q4 2025 Earnings After Market Close — 2026-03-19